| Expression pattern: |
DN |
| Associated gene: |
downstream targets of hsa-miR-197-5p, hsa-miR-222-3p, hsa-miR-330-5p and hsa-miR-486-3p |
| Associated microRNA: |
hsa-miR-197-5p, hsa-miR-222-3p, hsa-miR-330-5p, hsa-miR-486-3p |
| Biological function: |
Acts as an indicator for prognosis prediction and a biomarker for early gastric cancer screening; its abnormal expression may play an important role during gastric carcinogenesis. |
| Molecular mechanism: |
Predicted circRNA-miRNA interaction/ceRNA-related mechanism involving hsa-miR-197-5p, hsa-miR-222-3p, hsa-miR-330-5p, hsa-miR-486-3p and their downstream targets. |
| Biological pathway or process: |
ceRNA regulation (other); cell cycle (other); other pathway/process (other) |
| Detected method: |
Q
M
|
| Validation methods: |
Microarray; RT-qPCR; Sanger Sequencing; Clinical Sample Validation; ROC Analysis; Survival Analysis; Bioinformatics Analysis |
| Clinical significance: |
Low hsa_circ_0065149 expression levels in GC tissues were associated with tumor diameter and perineural invasion; GC patients with low hsa_circ_0065149 levels had longer overall survival than those in the high group; plasma exosomal hsa_circ_0065149 may serve as a screening biomarker for early gastric cancer. |
| Description: |
This study identified hsa_circ_0065149 as a SETD2-derived circRNA that is down-regulated in gastric cancer tissues and early gastric cancer plasma exosomes. Its expression is clinically associated with tumor diameter, perineural invasion, diagnostic ROC performance, and overall survival, with high expression indicating poorer survival. Bioinformatics analyses suggest a potential circRNA-miRNA-mRNA regulatory role involving hsa-miR-197-5p, hsa-miR-222-3p, hsa-miR-330-5p and hsa-miR-486-3p during gastric carcinogenesis. |
| Confidence score: |
0.636 |